Cargando…
Current Immunotherapeutic Approaches in Pancreatic Cancer
Pancreatic cancer is a highly aggressive and notoriously difficult to treat. As the vast majority of patients are diagnosed at advanced stage of the disease, only a small population is curative by surgical resection. Although gemcitabine-based chemotherapy is typically offered as standard of care, m...
Autores principales: | , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3172984/ https://www.ncbi.nlm.nih.gov/pubmed/21922022 http://dx.doi.org/10.1155/2011/267539 |
_version_ | 1782211923503218688 |
---|---|
author | Koido, Shigeo Homma, Sadamu Takahara, Akitaka Namiki, Yoshihisa Tsukinaga, Shintaro Mitobe, Jimi Odahara, Shunichi Yukawa, Toyokazu Matsudaira, Hiroshi Nagatsuma, Keisuke Uchiyama, Kan Satoh, Kenichi Ito, Masaki Komita, Hideo Arakawa, Hiroshi Ohkusa, Toshifumi Gong, Jianlin Tajiri, Hisao |
author_facet | Koido, Shigeo Homma, Sadamu Takahara, Akitaka Namiki, Yoshihisa Tsukinaga, Shintaro Mitobe, Jimi Odahara, Shunichi Yukawa, Toyokazu Matsudaira, Hiroshi Nagatsuma, Keisuke Uchiyama, Kan Satoh, Kenichi Ito, Masaki Komita, Hideo Arakawa, Hiroshi Ohkusa, Toshifumi Gong, Jianlin Tajiri, Hisao |
author_sort | Koido, Shigeo |
collection | PubMed |
description | Pancreatic cancer is a highly aggressive and notoriously difficult to treat. As the vast majority of patients are diagnosed at advanced stage of the disease, only a small population is curative by surgical resection. Although gemcitabine-based chemotherapy is typically offered as standard of care, most patients do not survive longer than 6 months. Thus, new therapeutic approaches are needed. Pancreatic cancer cells that develop gemcitabine resistance would still be suitable targets for immunotherapy. Therefore, one promising treatment approach may be immunotherapy that is designed to target pancreatic-cancer-associated antigens. In this paper, we detail recent work in immunotherapy and the advances in concept of combination therapy of immunotherapy and chemotherapy. We offer our perspective on how to increase the clinical efficacy of immunotherapies for pancreatic cancer. |
format | Online Article Text |
id | pubmed-3172984 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-31729842011-09-15 Current Immunotherapeutic Approaches in Pancreatic Cancer Koido, Shigeo Homma, Sadamu Takahara, Akitaka Namiki, Yoshihisa Tsukinaga, Shintaro Mitobe, Jimi Odahara, Shunichi Yukawa, Toyokazu Matsudaira, Hiroshi Nagatsuma, Keisuke Uchiyama, Kan Satoh, Kenichi Ito, Masaki Komita, Hideo Arakawa, Hiroshi Ohkusa, Toshifumi Gong, Jianlin Tajiri, Hisao Clin Dev Immunol Review Article Pancreatic cancer is a highly aggressive and notoriously difficult to treat. As the vast majority of patients are diagnosed at advanced stage of the disease, only a small population is curative by surgical resection. Although gemcitabine-based chemotherapy is typically offered as standard of care, most patients do not survive longer than 6 months. Thus, new therapeutic approaches are needed. Pancreatic cancer cells that develop gemcitabine resistance would still be suitable targets for immunotherapy. Therefore, one promising treatment approach may be immunotherapy that is designed to target pancreatic-cancer-associated antigens. In this paper, we detail recent work in immunotherapy and the advances in concept of combination therapy of immunotherapy and chemotherapy. We offer our perspective on how to increase the clinical efficacy of immunotherapies for pancreatic cancer. Hindawi Publishing Corporation 2011 2011-09-14 /pmc/articles/PMC3172984/ /pubmed/21922022 http://dx.doi.org/10.1155/2011/267539 Text en Copyright © 2011 Shigeo Koido et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Article Koido, Shigeo Homma, Sadamu Takahara, Akitaka Namiki, Yoshihisa Tsukinaga, Shintaro Mitobe, Jimi Odahara, Shunichi Yukawa, Toyokazu Matsudaira, Hiroshi Nagatsuma, Keisuke Uchiyama, Kan Satoh, Kenichi Ito, Masaki Komita, Hideo Arakawa, Hiroshi Ohkusa, Toshifumi Gong, Jianlin Tajiri, Hisao Current Immunotherapeutic Approaches in Pancreatic Cancer |
title | Current Immunotherapeutic Approaches in Pancreatic Cancer |
title_full | Current Immunotherapeutic Approaches in Pancreatic Cancer |
title_fullStr | Current Immunotherapeutic Approaches in Pancreatic Cancer |
title_full_unstemmed | Current Immunotherapeutic Approaches in Pancreatic Cancer |
title_short | Current Immunotherapeutic Approaches in Pancreatic Cancer |
title_sort | current immunotherapeutic approaches in pancreatic cancer |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3172984/ https://www.ncbi.nlm.nih.gov/pubmed/21922022 http://dx.doi.org/10.1155/2011/267539 |
work_keys_str_mv | AT koidoshigeo currentimmunotherapeuticapproachesinpancreaticcancer AT hommasadamu currentimmunotherapeuticapproachesinpancreaticcancer AT takaharaakitaka currentimmunotherapeuticapproachesinpancreaticcancer AT namikiyoshihisa currentimmunotherapeuticapproachesinpancreaticcancer AT tsukinagashintaro currentimmunotherapeuticapproachesinpancreaticcancer AT mitobejimi currentimmunotherapeuticapproachesinpancreaticcancer AT odaharashunichi currentimmunotherapeuticapproachesinpancreaticcancer AT yukawatoyokazu currentimmunotherapeuticapproachesinpancreaticcancer AT matsudairahiroshi currentimmunotherapeuticapproachesinpancreaticcancer AT nagatsumakeisuke currentimmunotherapeuticapproachesinpancreaticcancer AT uchiyamakan currentimmunotherapeuticapproachesinpancreaticcancer AT satohkenichi currentimmunotherapeuticapproachesinpancreaticcancer AT itomasaki currentimmunotherapeuticapproachesinpancreaticcancer AT komitahideo currentimmunotherapeuticapproachesinpancreaticcancer AT arakawahiroshi currentimmunotherapeuticapproachesinpancreaticcancer AT ohkusatoshifumi currentimmunotherapeuticapproachesinpancreaticcancer AT gongjianlin currentimmunotherapeuticapproachesinpancreaticcancer AT tajirihisao currentimmunotherapeuticapproachesinpancreaticcancer |